TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

GENPHARM

OncologyCardiovascularOphthalmology
Generics

GENPHARM is a generic drug manufacturer focused on Oncology, Cardiovascular, Ophthalmology.

1997
Since
4
Drugs
-
Trials
14
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

AMLODIPINE BESYLATE 2026-02-17
Manufacturing (CMC)
AMLODIPINE BESYLATE 2026-01-26
Manufacturing (CMC)
AMLODIPINE BESYLATE 2026-01-22
BENAZEPRIL HYDROCHLORIDE 2026-01-13
Manufacturing (CMC)
AMLODIPINE BESYLATE 2025-06-17
Labeling
BENAZEPRIL HYDROCHLORIDE 2025-03-04
Labeling
BENAZEPRIL HYDROCHLORIDE 2025-03-04
Labeling
AMLODIPINE BESYLATE 2025-01-03
Manufacturing (CMC)
DOXAZOSIN MESYLATE 2024-10-31
Labeling
DOXAZOSIN MESYLATE 2024-10-31
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 65%
0 drugs Phase 3: 11 Phase 2: 2 Phase 1: 3
Cardiovascular 18%
2 drugs Phase 2: 1
Ophthalmology 10%
0 drugs Phase 3: 2
Infectious Disease 5%
0 drugs Phase 3: 1
Respiratory 3%
0 drugs Phase 2: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Novartis big-pharma
Oncology, Cardiovascular, Ophthalmology, Respiratory
Baxter specialty
Infectious Disease, Cardiovascular, Oncology, Ophthalmology
GE HEALTHCARE specialty
Infectious Disease, Cardiovascular, Oncology, Respiratory
FOUGERA PHARMS other
Ophthalmology, Infectious Disease, Oncology, Cardiovascular
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular